Identifying Patients at Risk for Irinotecan (Camptosar) Myelotoxicity Based on UGT1A1 Genotype

Purpose: To evaluate a patient with colorectal adenocarcinoma for therapy with irinotecan (Camptosar) therapy based on UGT1A1 enzyme activity.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with colorectal cancer for irinotecan therapy?

Yes

Select an appropriate answer for each question

UGT1A1 genotype

Status of irinotecan chemotherapy

Does the patient have neutropenia ascribed to the chemotherapy?

Yes

Does the patient have a history of neutropenia ascribed to the chemotherapy?

Yes

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Should the dose of irinotecan be reduced?

Should UGT1A1 activity or SN-38 serum levels be monitored?

Should the aboslute neutrrophil count be monitored during therapy?

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Laboratory Tests
- Determining Isoniazid Acetylation Phenotype Based on Measurement of Urinary Isoniazid and Acetylisoniazid
- ABCB1 Polymorphism Test Prior to Therapy with Docetaxel or Irinotecan
Other Testing
- Methotrexate Toxicity & MTHFR (Methelenetetrahydrofolate Reductase) C677T Polymorphism
- Impact of CYP2C19 Phenotype on Clopidogrel Response
Criteria For Diagnosis
- Warfarin for Polymorphism in Cytochrome P450 (CYP) CYP2C9 | Medical Algorithm
Severity, Prognosis, Stage
- Predict Severe Toxicity Associated with Fluorouracil (5-FU) Therapy

Therapy

Selection
Pharmacogenetics
Dosage Adjustments
- Efavirenz Dose Reduction in HIV-1 Infected Patient Based on CYP2B6 Genotype

Monitoring

Response To Therapy
Adverse Effects

Specialty

Toxicology
Emergency Medicine
Critical Care
Genetics

Objective

risk factors
selection

ICD-10

T45.1 - Poisoning, antineoplastic and immunosuppressive drugs

Info

Purpose: To evaluate a patient with colorectal adenocarcinoma for therapy with irinotecan (Camptosar) therapy based on UGT1A1 enzyme activity.

Specialty: Toxicology, Emergency Medicine, Critical Care, Genetics

Objective: risk factors, selection

ICD-10: T45.1,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path